ArticleNPJ breast cancer2025

Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer.

Laura A Huppert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.